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1. Introduction
Bone defects resulting from trauma or 
disease are currently treated by transplan-
tation of autologous bone.[1] However, 
due to limited supply and transplantation-
associated donor site morbidity, great 
efforts were put into development of off-
the-shelf materials including recombinant 
osteogenic factors such as bone morpho-
genetic protein (BMP).[2] Although BMP 
has shown promising results in preclinical 
evaluations, its application in clinical set-
tings requires high doses that bear the 
risk of severe side effects.[3] Hence, a sig-
nificant effort has been directed toward 
the improved delivery of low-dose BMP.[4] 
A main reason for the low BMP-2 efficacy 
can be attributed to the limited availability 
of endogenous mesenchymal progenitor 
cells (MPCs) at the site of large bone 
defects.[5] Hence, it has been postulated 
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that the augmentation of MPC recruitment by presentation 
of recruitment factors would promote BMP-2-mediated bone 
formation.[5a,d,6] Indeed, some growth factors such as stromal-
derived factor (SDF-1), platelet-derived growth factor (PDGF-BB), 
fibroblast growth factor (FGF-2), or vascular endothelial growth 
factor (VEGF) have been co-delivered with BMP-2.[7] However, 
the simultaneous co-delivery of these growth factors only moder-
ately improved the healing of bone. Therefore, to closely recapit-
ulate the inherent healing cascade, being first the mobilization 
and only later the differentiation of MPCs, sequential delivery 
strategies have been developed. Such staged dual growth factor 
release approaches relied on layer-by-layer assembly of coat-
ings, core–shell microspheres, or heparin and fibronectin-based 
affinities.[5d,8]
Despite the successful growth factor release from the afore-
mentioned techniques, their complexity and limited tunability 
will likely restrict their widespread use for clinical applica-
tions. Optimally, synthetic fully defined extracellular matrices 
(ECMs) would be engineered to co-deliver growth factors in a 
time-controlled manner. We and others have previously devel-
oped synthetic poly(ethylene glycol) (PEG)-based hydrogels, 
that serve as biocompatible and tunable cell niches.[9] These 
fully defined niches allow the investigation of cell and growth 
factor functions in the absence of confounding and ill-defined 
signals that are present in naturally derived ECM hydro-
gels. Furthermore, our PEG hydrogel that is cross-linked by 
transglutaminase factor XIII (TG-PEG) enables the modular 
assembly of building blocks and therefore the independent tai-
loring of parameters such as stiffness, proteolytic (e.g., matrix 
metalloproteinase (MMP)-based) degradability, and sites for 
cell adhesion.[10] Importantly, the flexible design of TG-PEG 
hydrogels will concurrently enable the binding of multiple 
growth factors via different specific materials interactions and 
their tailored release.[10b,11] However, to the best of our knowl-
edge, the sequential, controlled release of multiple factors from 
such rationally engineered, synthetic materials has not been 
achieved so far.
We hypothesized that for the unbiased in vitro screening 
of recruitment factors, freshly isolated MPC populations from 
healing bones should be employed. Therefore, we implanted 
our modularly engineered TG-PEG hydrogels as an easy-
to-harvest cell-trap to isolate cells from bone defects. Cells were 
selected based on the stem cell antigen-1 (Sca-1), a marker 
found on multiple stem and progenitor cells,[12] likely allowing 
the isolation of different healing-relevant MPC populations. 
Thus, identified recruitment factors could then be ultimately 
used to design the next-generation healing materials with 
MPC-specific recruitment followed by differentiation, and thus 
enhance bone regeneration capacity.
The herein presented data show that healing bone defects 
contain a putative Sca-1+ MPC population that spontaneously 
differentiates toward osteogenic lineages in vivo. In vitro assays 
showed that PDGF-BB, FGF-2, and epidermal growth factor 
(EGF) induce the mobilization, but at the same time inhibit the 
osteogenic differentiation of freshly isolated Sca-1+ MPCs. Fur-
ther, the most efficient migration factor, PDGF-BB, significantly 
augmented the mobilization of endogenous Sca-1+ cells in vivo. 
However, PDGF-BB abrogated the bone healing activity of co-
delivered BMP-2, indicating the need for a sequential delivery 
strategy. Importantly, engineered hydrogels with fast release of 
PDGF-BB and the sustained delivery of low-dose BMP-2 pro-
moted bone formation, and enhanced the effect of low-dose 
BMP-2. Collectively, our data show that the use of cell-traps for 
the prospective isolation of tissue-specific progenitor cells ena-
bles the study of individual healing responses in vitro and the 
consequent translation of the acquired knowledge to advanced 
cell-free biomaterials-based healing strategies.
2. Results
2.1. Optimizing Synthetic TG-PEG Hydrogels for Bone Healing 
by Host Cell Recruitment
In order to have a highly controlled and modular system to 
recruit and grow MPCs, the previously described TG-PEG 
hydrogels were used.[10a,b] These synthetic TG-PEG hydrogels 
are formed by the transglutaminase (TG) enzyme factor XIII 
(FXIII) that cross-links equimolar blends of eight-arm PEG pre-
cursors functionalized with either a peptide sequence containing 
a glutamine (n-PEG-Gln) or a lysine (n-PEG-MMPsensitive-Lys 
or n-PEG-MMPnondegradable-Lys) under physiological conditions. 
The use of MMP-sensitive substrates and the cross-linking 
in the presence of a lysine-tagged RGD can be varied to turn 
TG-PEG into a cell substrate to accurately match specific 
demands (Figure 1A). As shown in earlier studies, the design 
of these TG-PEG hydrogels allows their modular tailoring with 
respect to presentation of cell adhesion sites, proteolytic deg-
radability, or mechanical properties (Figure 1B).[10c,11e,13] When 
formed at low initial polymer concentration (1.7–2.3% w/v), 
TG-PEG hydrogels were stable and did not swell in a physio-
logical buffer (Figure 1C). When exposed to MMP-1, hydrogels 
formulated with MMPsensitive cross-links continuously swelled, 
indicating proteolytic degradation of the hydrogel, while 
hydrogels which contained only MMPnondegradable cross-links 
remained stable over the evaluated 60 h at 37 °C (Figure 1D). 
Cultures of human bone marrow-derived MPCs (hBM-MPCs) 
in soft TG-PEG (1.7% w/v) hydrogels showed that in the 
absence of the integrin ligand RGD or the use of a nonde-
gradable linker peptide (PEG-MMPnondegradable-Lys), cells could 
not efficiently spread (Figure 1E). This indicated the necessity 
of cell adhesion and degradable sites in the hydrogel back-
bones. Next, we investigated the effect of stiffness in encap-
sulated hBM-MPCs in hydrogels ranging from 400 to 1000 Pa 
(Figure 1F,G). Even though, cell spreading was similar among 
these hydrogels, when hydrogels were implanted in calvarial 
defects after 4 weeks there was significantly more remodeling 
in the softest hydrogels (Figure 1H,I). Collectively, the softest 
hydrogels allowed the most efficient infiltration of healing-
associated cells, which likely contain a population of osteogenic 
MPCs.
2.2. Prospective Isolation of Healing-Associated MPCs through 
Hydrogel Traps
To isolate MPCs that participate in bone regeneration, soft, 
proteolytically degradable, and RGD-containing, but otherwise 
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Figure 1. TG-PEG hydrogels for bone healing. A) Scheme of modular-designed FXIII cross-linked TG-PEG hydrogels. Modular building blocks comprise 
eight-arm PEG precursors or cell-adhesion peptide RGD, which are functionalized with either a glutamine (n-PEG-Gln) or a lysine (n-PEG-MMPsensitive-
Lys or n-PEG-MMPnondegradable-Lys, and Lys-RGD) comprising FXIII recognition sites. B) Schematic representation of hydrogel properties achieved by 
varying modular components. C) Swelling of TG-PEG hydrogels formulated with different initial polymer concentrations. (n = 8). D) MMP-1-mediated 
degradation of different percentages TG-PEG hydrogels containing MMPsensitive (Deg) or MMPnondegradable (Non Deg) cross-links. Degradation of cross-
links results in the swelling of hydrogels (n = 5). E,F) Representative bright-field images of hBM-MPCs (2 × 106 cells mL−1) encapsulated in TG-PEG 
hydrogels after 5 days of 3D culture. E) When TG-PEG hydrogels were formed in absence of RGD or by the use of non-MMP degradable peptide linkers 
(scale bar = 200 µm). F) When TG-PEG hydrogels containing 50 × 10−3 M RGD and MMP degradable peptide linkers were formed with increasing initial 
polymer concentration (scale bar = 200 µm). G) Corresponding storage moduli of the hydrogels at the indicated initial polymer concentration (n = 3). 
H,I) Healing of murine calvarial bone defects 4 weeks after implantation of hydrogels of different stiffness that contained 0.2 µg BMP-2. H) H&E 
stainings (scale bar = 100 µm). I) Bone volume (BV) quantification by micro-CT analysis (n = 3). Graphs show individual data points and means for 
independent hydrogels or defects. *p < 0.05, **p < 0.01 (one-way ANOVA with Tukey–Kramer post hoc test).
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biologically inactive TG-PEG hydrogels were placed in 
murine critical-sized calvarial defects, where they served as 
a provisional healing matrix (Figure 2A). We and others have 
shown that matrix mineralization occurs from 2 weeks post-
implantation,[11b,14] therefore in order to prevent stem cells 
from undergoing differentiation, implants were harvested at an 
earlier time point of 1 week post-implantation. Remarkably, the 
implant material was infiltrated by various cell types 8 days post-
implantation (Figure 2B). Thus, we reasoned that this artificial 
niche could preserve the early cellular healing front, including 
endogenous and undifferentiated MPCs, and allow the facile 
isolation of these cells (thus, named from here on “cell-trap”).
Adv. Sci. 2020, 1903395
Figure 2. Sca-1+ mesenchymal cells are enriched in the calvarial cell-trap. A) Hydrogel cell-traps were implanted for 8 days into cranial critical-sized 
defects in mice. Infiltrated cells were harvested from cell-traps by enzymatic digestion and further analyzed by flow cytometry. B) Histological sec-
tion from the ventral side of an implanted hydrogel (H&E stain; scale bar left = 100 µm, scale bar right = 50 µm). Dotted line indicates the hydrogel, 
dashed square is a zoom-in image. C–E) Graphs show a representative flow cytometric analysis of one independent experiment and the quantification 
of all independent experiments for implant entrapped cells (n = 3), bone marrow (n = 6), and crushed calvaria (n = 3). F) Phenotypic assessment of 
nonhematopoietic and nonendothelial Sca-1+ (red), Alcam+/Sca-1− (blue), and Alcam−/Sca-1− (green) fractions (gray curve, isotype control). Graphs 
show individual data points and means for independent samples of implant entrapped cells (n = 3). *p < 0.05, ***p < 0.001, ****p < 0.0001 (one-way 
ANOVA with Tukey–Kramer post hoc test).
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To show the participation of various stromal cell populations 
in the early healing events of calvarial bone, cell-traps were har-
vested after 8 days of implantation and disintegrated by colla-
genase digestion. By fluorescence-activated cell sorting (FACS), 
we could isolate hematopoietic, mesenchymal, and endothelial 
cell fractions. We observed a slightly higher (not significant) 
content of nonhematopoietic and nonendothelial cells (CD45−/
Ter119−/CD31−; 3.5 ± 1.8%) in our cell-traps as compared to 
freshly isolated bone marrow (0.4 ± 0.2%) and crushed calvaria 
(2.3 ± 1.5%) (Figure 2C–E). To further divide the mesenchymal 
cell fraction, we used Sca-1 and Alcam, an earlier established 
marker pair for the isolation of endosteal niche cells from the 
bone marrow.[15] Interestingly, cell-traps contained large popu-
lations of Sca-1+/Alcam− cells (from here on termed Sca-1+; 
50.0 ± 3.7%; ≈30 000 cells per trap), as well as Alcam+/Sca-1− 
(from here on termed Alcam+; 6.8 ± 4.8%) and Alcam−/Sca-1− 
(from here on termed Alcam−; 24.2 ± 2.2%) cells (Figure 2D), 
corresponding to premature MPC subpopulations and osteo-
blasts, respectively.[15] In contrast, bone marrow and calvarial 
bones contained significantly lower frequencies of Sca-1+ cells 
(0.03 ± 0.04% and 1.5 ± 1.5%) and of Alcam+ cells (0% and 
2.7 ± 3.2%), respectively (Figure 2E). While the frequency of 
Alcam− cells was significantly higher in bone marrow and cal-
varial bones when compared to cell-traps. This suggested that 
cells similar to those present at the endosteal niche of the bone 
marrow are significantly enriched in the healing bone defect.
CD105, CD140a, CD29, and CD90 have been identified as 
phenotypic markers of freshly isolated and cultured murine 
MPCs.[12d,14,16] Thus, we next analyzed the expression pat-
terns of these markers within the isolated CD45−/Ter119−/
CD31− subpopulations (Figure 2F). A large fraction of Sca-1+ 
cells was found to be positive for CD29 (91 ± 2.6%) and nega-
tive for CD90 (10.1 ± 9.0%). Alcam+ cells showed an opposite 
pattern regarding CD90 (83.8 ± 6.5%) and CD29 (20.3 ± 4.4%) 
expression, whereas Alcam− cells showed a low expression of 
all tested markers. Within the Sca-1+ population, CD140a and 
CD105 were expressed by a subpopulation of 36.4 ± 6.4% and 
34.3 ± 5.8%, respectively. These data suggested that by the 
use of our cell-traps we can isolate large numbers of healing-
contributing cells, which likely contain multiple distinct MPC 
subpopulations suitable to study healing processes.
2.3. Trapped Sca-1+ Cells are Clonogenic and Differentiate into 
Different Mesenchymal Lineages
To further characterize the different trapped and freshly iso-
lated cell populations, we next assessed their in vitro clono-
genic and differentiation potential. CFU-F assay conducted 
with the freshly isolated cell populations revealed a significantly 
(≈100-fold) higher clonogenic frequency of the Sca-1+ population 
(3.5 ± 1.3%) compared to Alcam+ (0.03 ± 0.01%) and Alcam− 
(0.03 ± 0.02%) fractions, respectively (Figure S1A, Supporting 
Information). Sca-1+ cells showed a spindle-shaped morphology 
(Figure S1B, Supporting Information) and exhibited a strong pro-
liferative potential. In contrast, cells from both Sca1− fractions 
became senescent under evaluated culture conditions. Therefore, 
the clonogenic potential of the trapped CD45−/Ter119−/CD31− 
fraction resided almost exclusively within the Sca-1+ population. 
Furthermore, when cultured under commonly used differentia-
tion conditions, Sca-1+ cell differentiated into osteoblasts, adipo-
cytes, and chondrocytes (Figure S1C, Supporting Information), 
demonstrating that these cells also fulfill the currently accepted in 
vitro criteria for mesenchymal stem/progenitor cells (MPCs).[17]
2.4. Sca-1+ Cells Differentiate into Bone and Bone Marrow Cells
To analyze their in vivo differentiation potential, we harvested 
cell-traps from green fluorescent protein (GFP) mice (C57BL/6-
Tg(UBC-GFP)30Scha/J). Fresh, prospectively isolated GFP+ and 
Sca-1+, Alcam+, and Alcam− cell populations were encapsulated 
in BMP-2 releasing hydrogels and transplanted into subcuta-
neous pouches of immunocompromised nude recipient mice 
(HsdCpb:NMRI-Foxn1) (Figure 3A). 4 weeks post-implanta-
tion, heterotopic ossicles comprising a laminar bone shell and 
a highly vascularized trabecular compartment were formed. 
Implants containing Sca-1+ cells exhibited a strong fluorescent 
activity, indicating that Sca-1+ cells successfully engrafted and 
expanded in vivo (Figure 3B). While in implants formed with 
Alcam+ or Alcam− cells, the GFP signal was almost absent. 
Immunostainings further confirmed that GFP+ host cells were 
only present in ossicles with Sca-1+ cells. They further revealed 
that the cortical bone shell was exclusively formed by host-
derived cells and that transplanted Sca-1+ cells localized in the 
trabecular compartment (Figure 3C).
To assess the fate of Sca-1+ cells within the forming bone, 
ossicles were further analyzed 12 weeks after implantation 
when they appeared as complete bone marrows surrounded 
by a mineralized bone shell (Figure 3D). Histological analysis 
showed that within the newly formed heterotopic bone marrow, 
sinusoids, adipocytes, megakaryocytes as well as hematopoietic 
cell clusters existed. Immunohistochemical staining against 
GFP suggested that within the trabecular compartment, trans-
planted Sca-1+ cells differentiated into osteoblasts, osteocytes, 
adipocytes, as well as adventitial reticular cells of sinusoids 
(Figure 3E). This indicates that Sca-1+ cells contain popula-
tions that can undergo multiple differentiation paths within the 
forming bone and bone marrow.
2.5. Sca-1+ Cells Spontaneously Differentiate into Osteocytes 
and Localize to Endosteal Regions
Next, to assess their ability to participate in orthotopic bone 
regeneration, prospectively isolated Sca-1+ or Sca-1− cells (com-
prising both Alcam+ and Alcam− fractions) were encapsulated 
in hydrogels containing no exogenous BMP-2, and implanted in 
calvarial bone defects (Figure 4A). 12 weeks after implantation, 
bone defects treated with Sca-1+ cells showed a trend toward an 
increased calcium deposition when compared to defects treated 
with Sca-1− cells (Figure 4B,C). A side by side comparison of 
3D surface rendered micro-computed tomography (micro-CT) 
measurements with aligned fluorescence microscopy images 
revealed that GFP signals matched the calcified areas seen by 
micro-CT analysis (Figure 4D). Furthermore, anti-GFP immuno-
histochemical staining confirmed that Sca-1+ cells accumulated 
in endosteal regions and localized within fully matured bone, 
Adv. Sci. 2020, 1903395
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indicating that they differentiated into osteoblasts and osteo-
cytes, respectively (Figure 4E). Next, we wanted to confirm that 
Sca-1+ cells spontaneously differentiate toward the osteogenic 
lineage and form bone also in ectopic sites. Indeed, when Sca-
1+ cells were hydrogel-encapsulated in absence of growth factors 
and subcutaneously transplanted for 12 weeks, we found GFP 
expressing cell clusters seen in histological sections as bone nod-
ules (Figure S2, Supporting Information). This suggests that the 
Sca-1+ cell fraction contains one or more cell populations that 
can spontaneously differentiate toward the osteogenic lineage 
and might exert the same fate as in a bone defect. Collectively, 
these data indicate that Sca-1+ cells isolated from cell-traps are 
enriched in MPCs that can spontaneously differentiate to osteo-
cytes and form new bone. Therefore, for the remainder of this 
manuscript freshly isolated, cell-trap derived Sca-1+ cell popula-
tions will be referred to as Sca-1+ MPCs.
2.6. Growth Factors Promote a Differential In Vitro Migration  
of Sca-1+ MPCs
To mimic their in vivo mobilization, aggregates of 750 freshly 
isolated Sca-1+ MPCs were encapsulated within hydrogels 
and exposed to a library of 20 individual growth factors and 
cytokines with a previously described role in MPC migration. 
Under control culture conditions (i.e. no bioactive factor stim-
ulation), time-lapse microscopy did not reveal any migratory 
activity of Sca-1+ MPCs. For treatment groups, the extent of 
radial outgrowth varied significantly, decreasing from PDGF-
BB and FGF-2 to EGF and being negligible or even absent for 
all other factors (Figure 5).
The observed effects with Sca-1+ MPCs ranged from 
mesenchymal-type movement for PDGF-BB to collective migra-
tion of multicellular sprouts for FGF-2 and EGF. Migration 
Adv. Sci. 2020, 1903395
Figure 3. Trapped Sca-1+ cells exhibit osteolineage potential in heterotopic bone marrow. A) Nonhematopoietic, nonendothelial Sca-1+, Alcam+, and 
Alcam− populations were harvested using cell-traps from calvarial defects of mice ubiquitously expressing GFP (UBC-GFP). 1.5 × 104 freshly isolated 
cells of each fraction were incorporated into TG-PEG gels (10 µL) supplemented with 1 µg BMP-2 and implanted subcutaneously in immunocom-
promised NMRI nude receiver mice (n = 3). B,C) Heterotopic bone ossicles after 4 weeks of implantation. B) Macroscopic appearance (left column 
insert) as well as survival and participation of transplanted GFP+ cells in tissue formation (first column; fluorescent microscopy; scale bar = 500 µm) 
and H&E-stained tissue sections (H&E second column; scale bar = 50 µm). C) Anti-GFP stained tissue sections (GFP in red and counterstain with 
hematoxylin; scale bar = 50 µm). D,E) Tissue sections of heterotopic bone ossicles after 12 weeks of Sca-1+ cell implantation. D) Masson’s Goldner 
trichrome blue stain for detection of mineralized (bone) and nonmineralized (osteoid) areas (sin, sinusoids; mk, megakaryocytes; he, hematopoietic 
cell clusters; ad, adipocytes; gel, TG-PEG hydrogel. Scale bar upper panel = 500 µm; Scale bar lower panels = 50 µm). E) Anti-GFP stain (red, anti-GFP; 
blue, hematoxylin counterstain; black triangle, osteocytes; white triangle, bone lining cells (osteoblasts); white arrow, reticular processes; black arrow, 
adventitial reticular cells of sinusoids. Scale bar = 20 µm.
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modalities are regulated by the differential expression of 
cell–cell or cell–ECM interaction (e.g. integrin and cadherin) 
molecules. During development and healing, this allows coor-
dinated and oriented tissue guidance versus individual cell 
recruitment.[18] Thus, our data suggest that the selected growth 
factors could increase the mobility and the recruitment of 
Sca-1+ MPCs to the healing fracture by triggering different 
morphogenetic processes.
2.7. PDGF-BB, EGF, and FGF-2 Counteract Osteogenic  
Differentiation of MPCs
During bone fracture healing, the morphogenetic processes 
migration, proliferation, and osteogenic differentiation occur 
sequentially. In fact, it has been shown that some migration and 
proliferation promoting biomolecules can counteract osteogenic 
differentiation.[8a,19] Therefore, to assess if delivery of PDGF-BB, 
EGF, and FGF-2 affects the spontaneous osteogenic differentia-
tion of osteogenic progenitor cells, murine calvaria-derived MPCs 
were encapsulated in biomimetic cell-traps. The expression of 
early osteogenic differentiation markers was examined in the pres-
ence of these growth factors in vitro. PDGF-BB, EGF, and FGF-2 
significantly lowered expression of alkaline phosphatase (ALP) 
and osterix (SP7), additionally PDGF-BB reduced expression 
of Runx-2 (Figure 6A,C). Next, to mimic BMP-mediated bone 
regeneration in vitro, hydrogel-encapsulated MPCs addition-
ally to treatment with the recruitment factors were exposed to 
100 ng mL−1 BMP-2. The presence of only BMP-2 led to their 
efficient osteogenic differentiation as indicated by ALP activity 
(Figure 6B). However, treatment with 50 ng mL−1 PDGF-BB, 
EGF, or FGF-2 significantly reduced the BMP-2-induced ALP 
and osterix expression (Figure 6D). While the expression of 
Runx-2 was also significantly reduced for PDGF-BB and FGF-2, 
only a mild (not significant) reduction was observed for EGF. To 
exclude that this observation is specific to murine MPCs, analo-
gous experiments were performed with hBM-MPCs (Figure S3, 
Supporting Information). Similarly, PDGF-BB, and FGF-2 sig-
nificantly reduced the expression of ALP, Runx-2, and osterix, 
while EGF only reduced the expression of ALP. Thus, these 
data suggest that tested doses of PDGF-BB, EGF, and FGF-2 are 
repressing in vitro osteogenic differentiation of MPCs likely in 
favor of their migration and proliferation.
2.8. FGF-2, EGF, or PDGF-BB-Releasing TG-PEG Hydrogels  
Do Not Induce Bone Healing
It is well accepted that stem cells upon exposure to spe-
cific microenvironments can differentiate toward terminally 
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Figure 4. In healing bones, Sca-1+ cells spontaneously form osteoblasts and osteocytes. A) 2.5 × 104 fresh prospectively isolated, UBC-GFP mice-
derived Sca-1+ and Sca-1− cells were encapsulated in TG-PEG hydrogels and implanted for 12 weeks into 4 mm calvarial bone defects in C57BL/6 
receiver mice. B) Representative top views of 3D surface rendered micro-CT reconstructions of treated defects (scale bar = 3 mm) and C) quantitative 
assessment of bone formation within defects, shown as individual as individual data points and means (n = 4, Student’s t-test, n.s. not significant). 
D) Contribution of Sca-1+ cells to newly formed bone structures by sequential micro-CT (upper panel) and fluorescence microscopy evaluation 
(lower panel; scale bar = 500 µm). E) Representative images of anti-GFP stain-based localization of GFP positive cells within the bone wound (black 
triangle, osteocytes; white triangle, bone lining cells (osteoblasts); scale bar = 20 µm).
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differentiated tissue cells.[20] Thus, if osteogenic signals in 
healing bones are sufficiently strong, it should be expected 
that the accumulation of MPCs within a bone defect (by either 
recruitment or proliferation) can effectively stimulate bone 
healing. Therefore, we investigated if the selected migration 
factors FGF-2, EGF, or PDGF-BB as single treatment could 
improve the healing of calvarial defects (Figure S4, Sup-
porting Information). Histological evaluations showed that all 
growth factor releasing hydrogels were completely remodeled, 
while control hydrogels remained intact. However, neither 
Adv. Sci. 2020, 1903395
Figure 5. EGF, FGF-2, and PDGF-BB induce 3D migration of Sca-1+ MPCs in an in vitro growth factor and cytokine screen. Spheroids consisting of 
750 prospectively isolated Sca-1+ MPCs were embedded in TG-PEG hydrogels and cultured for 72 h in the presence of murine biomolecules: 10 ng mL−1 
EGF (n = 5) and FGF-2 (n = 4); 20 ng mL−1 IL-6 (n = 5) and TNFα (n = 9); 30 ng mL−1 IGF−1 (n = 6); 50 ng mL−1 BMP-2 (n = 5), BMP-4 (n = 3), HGF 
(n = 4), and SCF (n = 5); 100 ng mL−1 PDGF-BB (n = 5) and VEGF165 (n = 5); 150 ng mL
−1 CCL2 (n = 7), CCL5 (n = 5), CCL7 (n = 6), CCL21 (n = 4), 
CCL22 (n = 6), CXCL10 (n = 11), CXCL11 (n = 5), CXCL12 (n = 10), and CXCL13 (n = 4). Collective cell migration (gray bars) and single-cell migration 
(black) were quantified by automated image analysis. Data are depicted as mean ± SD. px, pixels. Scale bar = 200 µm.
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histological evaluations nor micro-CT-based analysis showed 
signs of bone regeneration in the growth factor releasing 
hydrogels. These observations indicate that FGF-2, EGF, or 
PDGF-BB could support the mobilization of healing-associated 
MPCs, but at the same time osteogenic differentiation is not 
induced.
2.9. PDGF-BB Promotes Perivascular MPC Recruitment
Next, to test if the best migration stimulating factor PDGF-
BB indeed augmented the number of Sca-1+ MPCs at the site 
of treatment, calvarial bone defects were treated with empty, 
PDGF-BB or BMP-2-releasing cell-traps. After 8 days of 
implantation, the cell-traps were harvested and processed for 
the analysis of recruited Sca-1+ cells by FACS and immuno-
logical staining of histological sections. The overall cell com-
position of the healing bone analyzed by FACS showed no 
significant difference between treatment groups with respect 
to the recruitment of Sca-1+ cells (Figure 7A), endothelial cells 
(CD31+), or hematopoietic cells (CD45+, Ter119+; Figure S5, 
Supporting Information). In contrast, in histological evalu-
ations, the ventral side of healing defects showed signifi-
cantly higher numbers of Sca-1+ cells after treatment with 
PDGF-BB, but not with empty or BMP-2 releasing hydrogels 
(Figure 7B,C). Furthermore, co-stains against CD31 and Sca-1 
revealed the presence of blood vessels on the ventral side of 
the healing defect, together with Sca-1+ cells which mostly 
localized in close proximity to these vessels (Figure 7B). This 
suggests that the native microenvironment of Sca-1+ MPCs 
could be the perivascular niche, from where they could be 
mobilized and expanded during bone healing, a process 
that upon PDGF-BB treatment might be mimicked and 
accelerated.
2.10. PDGF-BB Abrogates BMP-2-Induced Bone Healing
Next, we reasoned that MPCs that were accumulated through 
PDGF-BB delivery should efficiently undergo osteogenic dif-
ferentiation and therefore low concentrations of BMP-2 should 
result in efficient bone formation. To test BMP-2 and PDGF-
BB co-treatment, we had to first determine the dose-dependent 
osteogenic activity of BMP-2 in critical-sized calvarial defects. 
Both histological and micro-CT-based evaluations of bone 
defects revealed fast transition from a BMP-2 dose (0.2 µg) 
with a limited effect to a dose (1 µg) with almost complete bone 
healing (Figure 7D,E). While bone coverage was almost com-
plete for 0.5 and 1.0 µg of BMP-2, bone volume (BV) evalua-
tions showed a nearly linear dose–response. Since treatment 
with 0.2 µg BMP-2 led to only limited bone healing as com-
pared to the control (Figure 7E), this condition was selected to 
further evaluate the combinatorial treatments. However, unex-
pectedly, hydrogels releasing combinations of 0.2 µg BMP-2 
and 1 µg PDGF-BB completely abrogated the healing effects 
seen by hydrogels releasing only 0.2 µg BMP-2 (Figure 7F–H). 
These findings together with our in vitro differentiation evalu-
ations suggest that the presence of PDGF-BB additionally to 
the stimulation of MPC recruitment inhibits their osteogenic 
differentiation.
Adv. Sci. 2020, 1903395
Figure 6. FGF-2, EGF, and PDGF-BB reduce BMP-2-induced osteogenic differentiation of calvaria-derived MPCs in vitro. In vitro expanded mouse 
calvarial MPCs were encapsulated in TG-PEG hydrogels at a concentration of 1.5 × 106 mL−1 and cultured for 10 days in the presence of A,C) 0 and 
B,D) 100 ng mL−1 BMP-2 as well as 50 ng mL−1 of the indicated growth factors (n = 3). A,B) Colorimetric assessment of alkaline phosphatase activity 
(scale bars = 1 mm). C,D) Gene expression analysis of early markers of osteogenesis. Data are depicted as mean ± SD for all panels, *p < 0.05, 
**p < 0.01, ***p < 0.001, or ****p < 0.0001 (one-way ANOVA with Tukey–Kramer post hoc test).
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Figure 7. PDGF-BB delivery enhances osteoinductive effect of BMP-2 and increases recruitment of Sca-1+ cells to bone defects. Bone defects ⌀ 4 mm 
were created in the left and right parietal bones of C57BL/6 mice. Defects were treated with preformed control hydrogel implants containing indicated 
amounts of soluble or matrix-immobilized BMP-2 and PDGF-BB. Controls comprised defects that were left untreated or treated with empty hydrogel 
implants. A–C) The presence of MPCs in healing hydrogel implants was evaluated 8 days post-craniotomy. A) Cells were released by collagenase 
and quantified by FACS. B) Tissue sections were stained against Sca-1 and CD31 to localize Sca-1+ cells and blood vessels. Representative immuno-
fluorescence images of the most ventral side of the implant (scale bar = 50 µm). C) Quantitative assessment of Sca-1+ immunohistology of defects. 
D–L) Healing bone defects 4 weeks post-op. F) Schematic of strategy for delivery of soluble PDGF-BB and soluble BMP-2 or I) soluble PDGF-BB and 
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2.11. Augmenting Bone Formation by Sequential Delivery  
of PDGF-BB and BMP-2
Next, we reasoned that concentration and timeframe of 
growth factors delivery must be aligned with the natural 
healing cascade of natural healing cascade of bone. Accord-
ingly this growth factor delivery should first enhance the 
mobilization of MPCs and only later induce their osteogenic 
differentiation. Our in vitro release analysis showed that both 
PDGF-BB and BMP-2 are released in an initial burst. While 
the release of PDGF-BB lasted only for 10 h, the release of 
BMP-2 continued with a relative fast kinetic (Figure 7J). 
The growth factor payload is released through a combina-
tion of diffusion and hydrogel degradation, therefore, in 
the in vivo situation a faster release kinetic and therefore a 
faster exhaustion is expected. To obtain a persistent, low dose 
release of BMP-2, which is in tune with the cell-mediated 
degradation of the hydrogel, we have earlier established a 
streptavidin-modified TG-PEG (TG-PEG-Strep) hydrogel that 
efficiently binds biotinylated BMP-2 (bBMP-2; Figure 7I).[11c] 
We showed that this TG-PEG-Strep hydrogel-bound bBMP-2 
can induce a localized osteogenic differentiation of human 
BM-MPCs. Here, we confirmed the tight binding of bBMP-2 
to the TG-PEG-Strep hydrogel system (Figure 7J), while con-
firming that it is equally efficient in inducing the regenera-
tion of bone as nonbound, fast-release BMP-2 (Figure 7E,L 
and Figure S6, Supporting Information).
Based on these in vitro investigations, the combined use 
of native PDGF-BB and bBMP-2 in streptavidin-modified 
TG-PEG hydrogels results in a sequential fast (diffusion-
based) release of PDGF-BB and a continuous (hydrogel deg-
radation-coupled) slow release of bBMP-2. Importantly, when 
we applied these smart two-way dynamic release hydrogels 
containing a high concentration (1.0 µg) of fast-release PDGF-
BB and a low concentration (0.2 µg) slow-release bBMP-2, 
we observed an improved bone healing compared to either 
bBMP-2 or PDGF-BB alone (Figure 7L). Furthermore, the use 
of even lower concentrations of PDGF-BB (0.2 µg) for a two-
way dynamic release with bBMP-2 (0.2 µg) resulted in an even 
further and significantly improved healing of bone when com-
pared to bBMP-2 alone. Together, these findings indicate that 
for improved bone healing, first the augmentation of MPC 
numbers at the site of bone regeneration, and subsequently 
their osteogenic differentiation needs to be controlled by bal-
anced and staggered delivery of recruiting and differentiation 
factors. This is especially important for the design of next 
generation materials, which aim at co-opting natural healing 
processes such as the diametrically opposed, and thus sequen-
tially initiated mobilization and differentiation of stem and 
progenitor cells.
3. Discussion
In this study, we describe a new bioengineering approach 
for the screening of factors that promote bone healing by the 
recruitment and differentiation of endogenous MPCs. We show 
that the implementation of identified factors requires sophis-
ticated biomaterials engineering to enable sequential growth 
factor release.
Fracture healing is accomplished by an incompletely char-
acterized, complex interplay of various biomolecules and 
cells.[9a,21] While recently different mesenchymal stem and pro-
genitor cell populations have been characterized, their exact 
functional relation and role in bone healing remain obscure.[22] 
Additionally, it remains unknown how in vitro culture affects 
their function, which limits the information obtained through 
in vitro studies.[23] Therefore, in this study we freshly isolated, 
bone regeneration-derived mesenchymal (CD45−/Ter119−/
CD31−) cells, which likely contain multiple distinct MPCs sub-
populations, as a cell source to study and manipulate processes 
of bone regeneration.
Our provisional, fully defined TG-PEG hydrogel cell-traps 
were formed at a low stiffness, contained the integrin binding 
site RGD, and were degradable by MMP-1. This optimized 
formulation of TG-PEG hydrogels were infiltrated by a signifi-
cant number of mesenchymal cells, allowing their prospective 
(here Sca-1 and Alcam based) isolation of different subpopu-
lations (Figure 2C,D). Sca-1+-based sorting of healing-derived 
mesenchymal cells were significantly enriched for CFU-Fs 
(Figure S1, Supporting Information), reaching a comparable 
frequency as described for hBM-MPCs.[12a,14] The accumula-
tion of Sca-1+ MPCs (≈105 Sca-1+/Alcam− cells per defect) 
with a high CFU-F frequency at the wound site corresponds 
to the number of Sca-1+ isolated from all femora and tibia 
of one mouse[12a] and is consistent with the earlier reported 
elevation of cell populations named skeletal stem cells (SSCs) 
and bone cartilage stromal progenitor cells in fractured versus 
uninjured bone.[24]
When subcutaneously transplanted in BMP-2 containing 
PEG-hydrogels, Sca-1+ MPCs and their progeny contributed to 
the formation of ectopic ossicles, differentiated into trabecular 
osteocytes and osteoblasts, or localized to subsinosoidal struc-
tures of the heterotopic hematopoietic niches (Figure 3). In the 
absence of BMP-2, Sca-1+ MPCs formed isolated bone nodules 
and homed to the endosteum (Figure 4 and Figure S2, Sup-
porting Information) comparable to CD146+ human MPCs.[25] 
These data strongly suggest that trapped Sca-1+ MPCs con-
tain bone healing-associated stem and progenitor populations 
similar to fracture callus-derived SSCs[26] and could be used to 
study novel bone healing approaches, including their mobiliza-
tion to the site of regeneration.
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matrix-immobilized BMP-2. J) In vitro release of soluble and matrix-immobilized growth factors by ELISA. D,G,K) Representative top (left panels) and 
side views (upper right panels) of 3D surface rendered micro-CT measurements as well as H&E-stained coronal cross-sections (lower right panel) 
using D) soluble BMP-2, G) soluble PDGF-BB and soluble BMP-2, or K) soluble PDGF-BB and bound BMP-2 (scale bar for all panels = 1 mm). 
E,H,L) Quantitative assessment of parameters for bone regeneration in response to different treatments, using E) soluble BMP-2, H) soluble PDGF-
BB and soluble BMP-2, or L) soluble PDGF-BB and bound BMP-2. BVs of control gels are indicated by a solid gray line, of 0.5 µg soluble BMP-2 by a 
dotted line and of 1 µg soluble BMP-2 by a dashed line. Data are depicted as mean ± SD for n = 6 independent defects. n.s. not significant, *p < 0.05, 
***p < 0.001 (one-way ANOVA with Tukey–Kramer post hoc test).
www.advancedsciencenews.com
1903395 (12 of 16) © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedscience.com
In our 3D in vitro migration model, PDGF-BB, EGF, and 
FGF triggered the mobilization of Sca-1+ MPCs, while other 
known migration factors remained inactive (Figure 5). The 
inability of MPCs to respond to earlier identified mobilization 
factors can be explained by selective expansion of cellular enti-
ties or changes of cell function in cell culture expanded versus 
freshly isolated MPCs.[23a,27] Additionally, in contrast to Boyden 
chamber assays, in our 3D model the hydrogel-encapsulated 
MPCs, comparable to their in situ mobilization, need to initiate 
the mesenchymal cell migration program, including cell polari-
zation, cell adhesion, protease secretion, and actin strand con-
traction.[28] Interestingly, all identified mobilization factors are 
released during physiological platelet activation and other early 
healing associated events,[29] indicating their general role in the 
recruitment of MPCs in the native healing processes.
Our in vitro evaluations showed that the identified pro-
migratory factors PDGF-BB, EGF, and FGF inhibited the 
osteogenic differentiation of murine (Figure 6) and human 
BM-MPCs (Figure S3, Supporting Information), which is con-
sistent with earlier observations.[8a] Additionally, treatment with 
individual recruitment factors did not improve calvarial bone 
healing (Figure S4, Supporting Information). These findings 
suggest that in our system, growth factor-mobilized endog-
enous MPCs can promote bone healing only in the presence of 
an additional extrinsic osteogenic cue.
In PDGF-BB-treated calvarial defects, the total number of 
Sca-1+ cells (by FACS analysis) did not change as compared 
to control and BMP-2 treatment. This indicates that in healing 
bones not all Sca-1+ cell populations respond to growth factor 
treatment (Figure 7A). Of note, PDGF-BB-releasing hydrogels 
promoted the mobilization of Sca-1+ cells in the ventral part of 
the early (1 week) healing calvarial bone (Figure 7B,C). These 
Sca-1+ cells mostly co-localized with CD31+ endothelial cells, 
indicating their co-infiltration with vascular structures. Since 
BMP-2-induced bone regeneration in PEG hydrogels occurs 
from the ventral side,[11b] this suggests that perivascular Sca-1+ 
MPCs are crucial for bone regeneration.
Bone defects upon treatment with low-dose BMP-2 
(0.2 µg per bone defect) healed (Figure 7D,E), while in co-treat-
ment with PDGF-BB this healing was abrogated (Figure 7G,H). 
This finding together with the observed in vitro inhibition of 
MPC differentiation by PDGF-BB suggests the need for a 
sequential release of first PDGF-BB followed by BMP-2. Our 
earlier described streptavidin-modified hydrogels enabled 
diffusion-controlled fast release of PDGF-BB, and hydrogel 
remodeling-controlled slow release of bBMP-2.[11c,19] Using 
this sequential PDGF-BB and bBMP-2, release hydrogels 
(Figure 7I,J) significantly improved bone healing as com-
pared to hydrogels that simultaneously released PDGF-BB and 
bBMP-2 or bBMP-2 only (Figure 7K,L). These data together 
with our in vitro and in vivo evaluations of MPC mobilization 
suggest that PDGF-BB leads to an early enrichment of MPCs at 
the defect site, while subsequent slow release of bBMP-2 pro-
motes their osteogenic differentiation. To our knowledge, this 
is the first report showing a significant improvement of bone 
regeneration by sequential over simultaneous growth factor 
delivery. Additionally, the fact that low-dose (0.2 µg per defect) 
and high-dose (1.0 µg per defect) PDGF-BB were equally effi-
cient in promoting bone healing by low-dose BMP-2 indicates 
that the concentrations of both factors must be tightly balanced 
and at no point in time be too high. Therefore, by carefully 
adjusting dose and release properties of PDGF-BB and BMP-2, 
bone healing could likely be further optimized.
Our study was restricted to recruitment and manipula-
tion of MPCs involved in the healing of flat bone. It remains 
to be determined if the herein described principles also 
apply to healing of long bones. Additionally, earlier studies 
showed that in aged and diabetic animals the pool of MPCs 
is compromised.[5f,26,30] If and how in such compromised 
animals Sca-1+ MPCs dynamics and healing with combined 
PDGF-BB and BMP-2 treatments are affected will need further 
evaluations. While in vitro release profiles have been evaluated 
(Figure 7J),[11c] in vivo release kinetics remain unknown. Also, 
at this stage a cell-type selective infiltration of the implants 
cannot be excluded due to materials properties (including pore 
size, integrin adhesion, and degradability),[10] which are signifi-
cantly different from naturally occurring biomaterials.
The engineering of systems that specifically control bio-
logical processes by spatiotemporally tailoring the release of 
multiple factors will enable the study of healing mechanisms 
and the design of next-generation smart healing materials. The 
herein used synthetic material allows the study of the natural 
healing cascade in absence of uncontrollable confounding sig-
nals present in naturally derived biomaterials. Moreover, by 
tailoring the cell-trap degradation rate to the natural healing 
cascade, the spatial distribution of elements participating in 
bone healing can be conserved (Figure 2B). With respect to the 
here intended manipulation of the healing cascade, precisely 
balancing the migration, proliferation and differentiation of 
MPCs will be essential. To even further increase the body’s 
healing capacity, the decoration of smart hydrogels with inte-
grin binding sites that act synergistically with growth factor 
binding sites could be further explored.[31] Finally, the correla-
tion between the here reported murine MPCs and analogous 
human healing-associated MPCs will be important for transla-
tional approaches.
4. Conclusion
Taken together, in this study we amplified the efficiency of 
BMP-2 treatment by enhancing MPC recruitment to bone 
defects. To do so, we identified and manipulated cellular and 
molecular key players in bone healing. We envision the pre-
sented experimental sequence, which is based on i) prospective 
isolation of tissue stem and progenitor cells, ii) in vitro biomol-
ecule screen, iii) rational design of a biomaterial for spatiotem-
porally controlled biomolecule delivery, and iv) in vivo efficacy 
assessment, to be applied in other areas of in situ tissue engi-
neering, aiming at the augmentation of the natural healing 
cascade.
5. Experimental Section
Data Reporting: While experiments were not conducted in a 
randomized manner and by blinded investigators, all tissue specimens 
were processed and prepared for imaging by a blinded technician. Cell 
isolations from implants were conducted in three fully independent 
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experimental rounds. Sample size of each experimental round included 
at least three animals per condition. For bone regeneration experiments, 
sample sizes of n = 5 were chosen based on effects to be 50% increased 
compared to controls and a standard deviation of 25%. The power was 
set at 0.8 and the acceptable error rate at 5%. Samples were excluded 
if the positioning of implanted materials was significantly shifted after 
surgical interventions. To exclude a time and surgery-dependent bias, 
samples belonging to different experimental groups were conducted in a 
rotational basis and by a blinded investigator.
Preparation of TG-PEG Hydrogels: As described previously,[10] 
eight-arm PEG precursors containing the pending factor XIIIa substrate 
peptides glutamine acceptor (n-PEG-Gln) or lysine donor with 
(n-PEG-MMPsensitive-Lys) or without (n-PEG-MMPnondegradable-Lys) an 
additional MMP-sensitive linker were stoichiometrically mixed (final 
dry mass content as indicated—1.7%, 2.1%, or 2.3% w/v) in Tris-Buffer 
(TBS, 50 × 10−3 M, pH 7.6) containing 50 × 10−3 M calcium chloride. 
Before use, all solutions were sterilized using a 0.22 µm syringe filter. 
When indicated, 50 × 10−6 M Lys-RGD peptide (Ac-FKGG-RGDSPG-NH2), 
indicated amounts of growth factors and/or cells were added to the 
precursor solution prior to initiation of cross-linking by 10 U mL−1 
thrombin-activated factor XIIIa and vigorous mixing.
Equilibrium Swelling Measurements: Hydrogels were weighted after 
termination of FXIIIa cross-linking and after 1 day of incubation in Tris-
Buffer (TBS, 50 × 10−3 M, pH 7.6). The swelling ratio was determined as 
the swollen gel mass divided by the gel’s initial mass.
Degradation of Gels by MMP-1: Hydrogels were immersed in 100 µL 
digestion buffer (50 × 10−3 M Tris, 50 × 10−3 M NaCl, 10 × 10−3 M CaCl2, 
0.05% w/v Brij 35, pH 7.5) containing 50 × 10−9 M MMP-1 (PeproTech, 
United Kingdom). The weight of hydrogels was repeatedly measured 
during incubation at 37 °C.
Rheological Analysis: Hydrogel stiffness was characterized by in situ 
rheometry. Gelation of 80 µL hydrogels at the indicated final dry mass 
content was analyzed on a rheometer (MCR 301, Anton Paar) equipped 
with 20 mm plate–plate geometry (PP20, Anton Paar) at 37 °C in a 
humidified atmosphere. The measuring gap size was set at 0.2 mm 
to ensure proper loading of the space between the plates and gel 
precursors. The evolution of storage modulus (G′) at a constant angular 
frequency of 1 Hz and constant shear strain of 4% was recorded for 
30 min when equilibrium was reached.
Calvarial Defect Model: All in vivo experiments were approved by 
the veterinary offices of the canton of Zurich and were conducted in 
accordance with the Swiss law of animal protection. Adult wild-type 
C57BL/6 mice (purchased from Harlan) or transgenic C57BL/6-Tg(UBC-
GFP)30Scha/J female mice at the age of 10–12 weeks at the start of the 
experiments were used. 4 mm diameter craniotomies were created in 
the parietal bones of the skull, one on each side of, but not touching 
the sagittal suture. Defects that showed signs of dura injuries were not 
used for transplantations. Preformed sterile TG-PEG hydrogel disks 
with a diameter of 4 mm were then placed in the defects. The TG-PEG 
hydrogel disks were in advance produced by placing 14 µL of complete 
TG-PEG solution supplemented with the indicated growth factors 
between two sterile hydrophobic glass microscopy slides (obtained by 
treatment with SigmaCote, Sigma-Aldrich, cat. no. SL2) separated by 
spacers (≈1 mm thickness). After incubating the forming matrices at 
37 °C for 30 min, hydrogel disks were released from the glass sides and 
stored in humidified atmosphere until their application. After placing the 
hydrogel into the defect, the skin was closed with sutures. Animals were 
euthanized 8 days post-craniotomy for cell isolation and 4 or 12 weeks 
post-craniotomy for analysis of bone healing.
Prospective Isolation and Flow Cytometry Analysis of Entrapped Cells: 
To isolate cells from defect sites, the defect sites were trimmed using 
surgical scissors in order to retrieve the hydrogel. Hydrogels were 
then fragmented by a scalpel and pieces were incubated in Dulbecco’s 
modified Eagle medium (DMEM)/F-12 + GlutaMAX (Gibco Life 
Technologies, cat. no. 31331-028) supplemented with 1% v/v penicillin/
streptomycin solution (P/S; Gibco Life Technologies, cat. no. 15140-122) 
and 0.1% Collagenase A (Roche Applied Science, cat. no. 10103586001) 
at 37 °C for 50 min. After addition of trypsin (final conc. 0.025%; Gibco 
Life Technologies, cat. no. 25050) followed by a second incubation step 
for 10 min at 37 °C, cells were washed with FACS buffer (phosphate 
buffered saline (PBS) pH 7.2 with 1 × 10−3 M ethylenediaminetetraacetic 
acid) and filtered through a 100 µm cell strainer (BD Falcon, cat. no. 
352350). Red blood cells were lysed by incubation with RBC lysis buffer 
(Biolegend, cat. no. 420301) for 10 min on ice and cells were washed 
and re-suspended in FACS buffer. Cells were stained with monoclonal 
antibodies for 30 min at 4 °C. Employed antibodies can be found in the 
Supporting Information. Flow cytometric experiments and sorting were 
performed with a LSRII (BD Biosciences) and AriaIII (BD Biosciences), 
respectively. Gates were defined according to the fluorescence intensity 
of the isotype control. Data were analyzed using FlowJo 7.6.4. Software 
(TreeStar) and shown as contour plots or histograms of fluorescence 
intensity.
Cell Culture: Freshly sorted cells were cultured as adherent cultures on 
collagen-coated plates at 37 °C with 5% CO2 in maintenance medium: 
Minimal essential medium alpha (MEMα; Gibco Life Technologies, 
cat. no. 22571-020) with 10% v/v fetal calf serum (FCS; Gibco Life 
Technologies, cat. no. 10500) and 1% P/S supplemented with 5 ng mL−1 
FGF-2 (Peprotech, cat. no. 100-18B).
Human Bone Marrow Cells: hBM-MPCs were isolated from bone 
marrow aspirates of three healthy donors and cultured as described 
previously.[32] Informed consent was obtained from the local ethical 
committee (University Hospital Basel; Prof. Dr. Kummer; approval date 
26/03/2007 Ref Number 78/07). hBM-MPCs were cultured at 37 °C in a 
humidified atmosphere and 5% CO2 using MEM α supplemented with 
10% FCS, 1% P/S, and 5 ng mL−1 FGF−2.
CFU-F Assay: 102 to 104 isolated and freshly sorted cells were seeded 
on a 35 mm collagen-coated dish (Techno Plastic Products, cat. no. 
92006) and cultured for 11 days in maintenance medium supplemented 
with 5 ng mL−1 FGF-2 at 37 °C with 5% CO2. After fixation with 4% 
paraformaldehyde for 10 min and stained with 0.05% w/v crystal violet 
solution for 30 min. Cell clusters counting > 50 cells were scored as 
colony.
In Vitro Differentiation: To assess in vitro differentiation, sorted Sca-
1+ cells were plated at 5 × 103 cells well−1 in a collagen-coated 96-well 
plate (Techno Plastic Products, cat. no. 92096) in maintenance medium. 
The next day, medium was replaced with the following differentiation 
induction medium. To assess osteogenic differentiation, maintenance 
medium was replaced with osteogenic induction medium: DMEM high 
glucose (Gibco Life Technologies, cat. no. 41965-039) with 10% v/v 
FCS and 1% v/v P/S modified with β-Glycerophosphate (10 × 10−3 M; 
AppliChem, cat. no. A2253), dexamethasone (0.1 × 10−6 M; AppliChem, 
cat. no. A2153), and L-ascorbic acid (0.05 mg mL−1; AppliChem, cat. no. 
A1052). Osteogenic induction medium was changed every 3–4 days. 
After 4 weeks, Alizarin red S staining was performed to assess for 
calcium deposition. To assess adipogenic differentiation, maintenance 
medium was replaced with adipogenic induction medium: DMEM low 
glucose (Gibco Life Technologies, cat. no. 31885-02) with 20% v/v FCS 
and 1% v/v P/S modified with IBMX (0.5 × 10−3 M; AppliChem, cat. no. 
A0695), indomethacin (60 × 10−6 M; Sigma-Aldrich, cat. no. I7378), and 
dexamethasone (1 × 10−6 M). Adipogenic induction medium was changed 
every 2–3 days. After 10 days, lipid droplet formation was measured 
using Oil red O staining. To assess chondrogenic differentiation, 
maintenance medium was replaced with chondrogenesis medium: 
DMEM high glucose with 10% v/v FCS and 1% v/v P/S modified with 
dexamethasone (0.1 × 10−6 M), L-ascorbic acid (200 × 10−6 M), and 
TGF-β3 (20 ng mL−1; PeptroTech, cat. no. 100-36E). Chondrogenic 
induction medium was changed every 2–3 days. After 4 weeks, toluidine 
blue staining was performed to assess for chondrogenesis. In all 
experiments, sorted Sca-1+ MPCs cultured in maintenance medium were 
used as controls.
Encapsulation of Single Cells and Microtissues in TG-PEG Hydrogels: 
For encapsulating freshly isolated single dispersed cells or microtissues 
in TG-PEG gels, cell or microtissue suspensions were diluted in 
maintenance medium without FGF-2 and added to the complete TG-PEG 
solution. Desired volumes of this mixture were then sandwiched between 
sterile hydrophobic glass microscopy slides (obtained by treatment with 
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SigmaCote) separated by spacers (≈1 mm thickness) and clamped with 
binder clips. To prevent sedimentation of cells or microtissues, the 
forming matrices were slowly rotated at room temperature (RT) until the 
onset of gelation and then incubated for additional 30 min at 37 °C.
3D Microtissue Migration Assay: For the following paragraph, 
maintenance medium without FGF-2 was used. For microtissue 
formation, freshly harvested Sca-1+-enriched MPCs were suspended 
(final conc. 25 000 cells mL−1) in maintenance medium supplemented 
with 0.2% w/v methyl cellulose (Sigma-Aldrich, cat. no. M0512). Droplets 
of 30 µL were placed in nonadhesive cell culture dishes (Greiner bio-one, 
cat. no. 633180) and cultured overnight as hanging drops. The resulting 
spheroids (≈750 cells) were harvested in maintenance medium and 
washed once with maintenance medium. Sca-1+ MPC microtissues were 
encapsulated in TG-PEG hydrogels (final conc. ≈250 microtissues mL−1), 
hydrogels were thereafter released and transferred into a 24-well plate 
(Techno Plastic Products, cat. no. 92024). Gels were then cultured for 
4 days in 500 µL maintenance medium in the presence of the indicated 
murine biomolecules. All biomolecules were purchased as lyophilized 
powder from PeproTech and re-suspended in 50 × 10−3 M Tris pH 7.6 
supplemented with 0.1% bovine serum albumin (BSA, AppliChem, 
cat. no. A1391). Samples were fixed with 4% v/v paraformaldehyde in 
PBS, permeabilized with Triton X-100 (Sigma-Aldrich, cat. no. T-8787) 
and stained for f-actin with Rhodamine Phalloidin (Life technologies, 
cat. no. R415). Z-stack images of microtissues were acquired at 10x 
magnification using a confocal laser scanning microscope (Leica TCS 
SP5). Cell migration was quantified by an automated image analysis 
script written in MATLAB (R2013a, MathWorks Inc., USA) that measures 
the distance of f-actin stained pixels from the microtissue center and 
distinguishes between collective versus single cell migration. Pixels 
belonging to the connected network originating from the spheroid 
center were recognized as collective migration and residual pixels as 
single cell migration. The script’s accuracy in distinguishing between 
collective and single cell migration was verified at multiple time points. 
Data were displayed as histogram depicting the amount of pixels relative 
to the migration distance.
Gene Expression Analysis Using qRT-PCR: To measure the expression 
of osteogenic markers in TG-PEG gels, mouse MPCs or human 
BM-MPCs (n = 3) were encapsulated in TG-PEG gels (1.7% PEG, 
50 × 10−6 M RGD) at a final concentration of 1.5 × 106 mL−1. 
Gels were cultured for 10 days in MEMα, 10% FCS, 1% P/S, 
10 × 10−3 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 
1 × 10−3 M sodium pyruvate, 2 × 10−3 M L-glutamine, 50 × 10−6 M, 
10−1 L-ascorbic acid, and 10 × 10−3 M β-glycerol phosphate. The 
following recombinant growth factors were used for osteogenic 
differentiation experiments: human BMP-2 (100 ng mL−1, produced 
as previously described[33]), FGF-2, PDGF-BB, EGF (each 50 ng mL−1, 
PeproTech, mouse or human, respectively). Medium and growth 
factors were replaced after 5 days. After 10 days, gels (40 µL) were 
digested in 50 µL collagenase A (2 mg mL−1, Roche) for 30 min at 
37 °C. Next, cells were pelleted by a benchtop centrifuge (5415 R, 
Eppendorf ) and total RNA was isolated from the cells by the RNeasy 
Micro Kit (Qiagen) according to the manufacturer’s instructions. For 
quantitative real-time PCR (qRT-PCR), 100 ng RNA was converted 
into 20 µL cDNA by means of the high-capacity cDNA reverse 
transcription kit (Applied Biosystems). qRT-PCR was carried out 
using TaqMan Universal PCR Master Mix (Applied Biosystems) 
and the StepOnePlus Real-Time PCR System (Applied Biosystems). 
The following TaqMan primer/probe sets were used for gene 
expression tests: Human: Hs01029144_m1 (ALPL); Hs01047973_m1 
(RUNX2); Hs01866874_s1 (SP7). Mouse: Mm00475834_m1 
(Alpl); Mm00501584_m1 (Runx2); Mm04209856_m1 (Sp7). Data 
were normalized on human Hs02758991_g1 (GAPDH) or mouse 
Mm99999915_g1 (Gapdh) and relative gene expression was 
calculated by the comparative Ct method.
Ectopic Bone Formation Model: For subcutaneous transplantation 
assays, 15 000 fresh (uncultured), prospectively isolated cells (from 
calvarial cell-traps) were encapsulated in 10 µL TG-PEG hydrogels 
in the presence or absence of total 1 µg BMP-2. After completed 
polymerization, hydrogels were released from glass slides and stored in 
humidified atmosphere until application. Hydrogels were then implanted 
in subcutaneous pouches of immunocompromised nude mice (four 
samples per mouse; HsdCpb:NMRI-Foxn1 mutant mice purchased 
from Harlan) at the age of 5–10 weeks and retrieved after 4 or 12 weeks 
post-implantation.
Orthotopic Bone Formation Model: 25 000 prospectively isolated, 
calvarial cell-traps-derived cells were encapsulated in 10 µL TG-PEG 
hydrogels. After completed polymerization, hydrogels were released 
from glass slides and stored in humidified atmosphere until application. 
Hydrogels were then implanted in 4 mm diameter calvarial defects of 
9–10 weeks old C57/BL6 mice (two samples per mouse) and retrieved 
12 weeks post-craniotomy.
Histological Staining and Immunohistochemistry of Ectopic and 
Orthotopic Bone Formation: Samples were fixed in 4% v/v formalin, 
decalcified with USEDECALC (MEDITE, cat. no. 40-3310-00) and 
embedded in paraffin. For histological stainings, sections (4 µm) were 
stained with hematoxylin & eosin (H&E) and Masson’s trichrome 
(Sigma-Aldrich, cat. no. HT15-1KT). For anti-GFP immunohistochemistry 
of ectopic bone formation, sections (4 µm) were stained with primary 
antibody against GFP (Abcam, cat. no. ab290). Alkaline phosphatase-
conjugated anti-rabbit antibody was used as secondary antibody. 
Incubations were performed on Leica BondMax instruments using 
Refine HRP-Kits (Leica DS9800) including all buffer-solutions from 
Leica Microsystems, processed according to the manufacturers’ 
guidelines. Antigen Retrieval was performed with Epitope-Retrieval 
buffer 1 (Leica AR9961) at 100 °C for 10 min. Images of histological 
staining and immunohistochemistry were acquired using a Zeiss 
200M inverted microscope. For orthotopic bone formation, calvaria 
were fixed with acetone for 4 h at −20 °C, decalcified in USEDECALC 
(MEDITE, D123501) and then embedded in cryomolds. Tissue sections 
of 5 µm thickness were cut on a cryostat (Leica CM3050S) and re-fixed 
with acetone for 10 min. After rehydration in PBS for 10 min, soaking 
in blocking solution containing 1.5% BSA and 0.5% Tween-20 they 
were exposed to anti-GFP antibody (Abcam, cat. no. ab290) overnight 
at 4 °C. Then sections were incubated with a biotinylated secondary 
goat anti-rabbit antibody for 1 h at RT, followed by incubation with an 
avidin-biotin-peroxidase complex for 1 h at RT (Vector Laboratories Inc., 
PK-6101). Peroxidase was revealed by incubation with AEC (3-amino-9-
ethylcarbazole) red substrate (Vector Laboratories Inc., SK-4200) prior 
blocking with 3% H2O2. Between individual incubation steps sections 
were rinsed three times with PBS containing 0.5% Tween-20.
Microcomputed Tomography at Endpoints: After fixation in formalin and 
storage in PBS, complete skulls were scanned in a micro-CT 40 (Scanco 
Medical AG) operated at energy of 70 kVp and intensity of 114 µA. 
Scans were executed at a high-resolution mode resulting in a voxel size 
of 10 µm. In reconstructed images, bone tissue was segmented from 
background using a global threshold of 9.8% of maximum gray value. 
A cylindrical mask with a diameter of 3 mm was manually placed at 
the bone defect. BV, connectivity, and trabecular thickness within this 
mask were measured using the ImageJ plugin BoneJ.[34] Coverage was 
measured in a dorsoventral projection of the cylindrical mask.
Recombinant Protein Production: Recombinant proteins BMP-2 and 
TG-Streptavidin were produced as described previously.[11c,33] BMP-2 was 
biotinylated as described previously.[11c]
Immunohistochemistry and Histomorphometric Analysis of Cell Traps: 
Calvaria were harvested, fixed in 100% acetone for 4 h at −20 °C and 
embedded in cryomolds. Vertical sections of calvarial bones were cut on a 
cryostat (Leica CM3050S) at a thickness of 5 µm. The slides were re-fixed 
with 100% acetone for 10 min and rehydrated in PBS for 10 min, soaked 
in blocking solution containing 1.5% BSA and 0.5% Tween-20 in PBS 
for 45 min at RT and exposed to anti-CD31 antibody (BD Pharmingen 
550274) overnight in a humidified chamber at 4 °C. The slides were then 
incubated with a goat anti-rat Alexa-Fluor 546 secondary antibody for 1 h 
in the dark at RT. After washing, the slides were soaked in rat serum for 
1 h at RT and exposed to anti-Sca-1 antibody (R&D Systems AF1226) for 
at least 2 h at RT. The slides were incubated with a donkey anti-goat FITC-
conjugated secondary antibody for 1 h in the dark at RT. The specimens 
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were washed three times in PBS, mounted in fluorescent mounting 
medium (DAKO S3023), and analyzed by fluorescent microscope 
(Leica BM550B). Images were processed in Fiji and Adobe Photoshop 
CS6 to create gray scale images. The relative number of Sca-1+ cells on 
tissue sections was assessed by thresholding of gray scale images and 
quantification of pixels above the threshold (defined to exclude unspecific 
staining), and each value was normalized to the control gel).
Growth Factor Release In Vitro: TG-PEG hydrogels (10 µL) containing 
1 µg of PDGF-BB, 0.2 µg of BMP-2 or bBMP-2 were incubated in 250 µL 
of 0.1% BSA in Tris buffer at 4 °C. After 1, 4, 10, 22, and 48 h, the solution 
was collected and frozen, and replaced by fresh buffer. Growth factor 
concentrations in these collected supernatants were then measured by 
the PDGF-BB ELISA development kit (Peprotech, cat. no. 900-K04) or 
BMP-2 ELISA development kit (Peprotech, cat. no. 900-T255) according 
to manufacturer’s guidelines.
Statistical Analysis: Where sufficient samples (n > = 5) were available, 
normal distribution was assessed using a Kolmogorov–Smirnov 
test. All mean values were compared by one-way analysis of variance 
(ANOVA) using MATLAB (R2013a, MathWorks Inc., USA) followed 
by a Tukey–Kramer post hoc test for pairwise comparison. Statistical 
significance was accepted for p < 0.05, and reported as follows *p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001. Further information is found 
in the particular figure legends.
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